APOB and metabolic syndrome: ApoB has been proposed as a better predictor of cardiovascular risk than LDLC in patients with mild-to-moderate hypertriglyceridemia, diabetes, and metabolic syndrome characterized by high numbers of small dense LDL particles (13).